GlobeNewsWire
14 Aug 2026, 12:45 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Silexion has transitioned SIL204 into an active Phase 2/3 clinical program for locally advanced pancreatic cancer, initiating its first site in July 2026. — Moving from regulatory preparation to active late-stage clinical trials is a major value inflection point for biotech companies.
+0.80Silexion has secured clinical trial authorizations from regulators in both Israel and Germany and initiated GMP clinical supply manufacturing. — Regulatory approvals and manufacturing readiness are critical operational prerequisites that reduce execution risk for the trial.
+0.50New preclinical data shows SIL204 supports a coordinated immune-sensitization signature across four KRAS mutations, suggesting potential for combination therapy with anti-PD-(L)1 inhibitors. — Expanding the therapeutic profile and identifying combination pathways increases the drug's total addressable market and probability of success.
+0.40Continue reading
6 related stories
Search tags
The company closed a public offering with gross proceeds of approximately $2.5 million to support the clinical trial and maintain Nasdaq listing compliance. — While providing necessary liquidity, the small size of the offering relative to Phase 2/3 costs suggests a continued need for future capital.
+0.30Which stocks this story touches
The company successfully transitioned its lead asset into a Phase 2/3 clinical program and expanded its therapeutic profile with positive preclinical data.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
3h ago
